J. Warren Huff's most recent trade in Reata Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 275,436 Employee Stock Option (right-to-buy) done . Disclosure was reported to the exchange on July 6, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2023 | 275,436 | 275,436 | - | - | Employee Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2023 | 72,564 | 122,480 (0%) | 0% | 0 | Class A common stock | |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2023 | 11,656 | 49,916 (0%) | 0% | 0 | Class A common stock | |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | 01 Mar 2023 | 75,000 | 111,158 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | 01 Mar 2023 | 75,000 | 212,903 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 88.59 per share. | 01 Mar 2023 | 12,826 | 47,093 (0%) | 0% | 88.6 | 1,136,255 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.20 per share. | 01 Mar 2023 | 12,132 | 90,922 (0%) | 0% | 82.2 | 997,250 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.31 per share. | 01 Mar 2023 | 9,660 | 81,262 (0%) | 0% | 83.3 | 804,775 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 81.49 per share. | 01 Mar 2023 | 8,104 | 103,054 (0%) | 0% | 81.5 | 660,395 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 84.33 per share. | 01 Mar 2023 | 7,439 | 73,823 (0%) | 0% | 84.3 | 627,331 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 85.25 per share. | 01 Mar 2023 | 6,395 | 67,428 (0%) | 0% | 85.3 | 545,174 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 89.49 per share. | 01 Mar 2023 | 5,742 | 41,351 (0%) | 0% | 89.5 | 513,852 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 90.57 per share. | 01 Mar 2023 | 4,623 | 36,728 (0%) | 0% | 90.6 | 418,705 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 87.61 per share. | 01 Mar 2023 | 4,034 | 59,919 (0%) | 0% | 87.6 | 353,419 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 86.44 per share. | 01 Mar 2023 | 3,475 | 63,953 (0%) | 0% | 86.4 | 300,379 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 91.12 per share. | 01 Mar 2023 | 570 | 36,158 (0%) | 0% | 91.1 | 51,938 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 190,950 | 190,950 | - | - | Employee Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 47,025 | 47,025 (0%) | 0% | 0 | Class A common stock | |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 44,600 | 44,600 | - | - | Employee Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 175.00 per share. | 09 Nov 2020 | 64,970 | 0 (0%) | 0% | 175.0 | 11,369,756 | Class A common stock |
| Reata Pharmaceuticals Inc ... | J. Warren Huff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 175.06 per share. | 09 Nov 2020 | 16,687 | 64,970 (0%) | 0% | 175.1 | 2,921,291 | Class A common stock |